Author:
Li Ying,Wang Yi,Qu Haibin,Cheng Yiyu
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Redfearn D P, Skanes A C, Lane J, Stafford P J. Signal-averaged P wave reflects change in atrial electrophysiological substrate afforded by verapamil following cardioversion from atrial fibrillation. Pacing Clin Electrophysiol, 2006, 10: 1089–1095
2. Cooper-DeHoff R M, Aranda J M, Jr, Gaxiola E, Cangiano J L, Garcia-Barreto D, Conti C R, Hewkin A, Pepine C J. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart, 2006, 151(5): 1072–1079
3. Shaheen N, Mahboob T. Antihypertensive and metabolic effects of verapamil: role of Na-K-ATPase and electrolytes homeostasis in male and female rats. Pak J Pharm Sci, 2004, 17(2): 1–11
4. Hansen J F. Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs, 1991, 42: 43–53
5. Yoshida M, Loo J A, Lepleya R A. Proteomics as a tool in the pharmaceutical drug design process. Curr Pharm Des, 2001, 7: 291